BRVE insider trading
NasdaqGM HealthcareBraveheart Bio, Inc.: insider trade history from SEC Form 4 filings.
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Company website: www.braveheart.bio
BRVE insider activity at a glance
FilingIQ tracks 19 insider transactions for BRVE in filings since Aug 7, 2026. The most recent transaction is dated Aug 7, 2026.
Across the full history, 13 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest BRVE Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at BRVE
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for BRVE?
- FilingIQ tracks 19 Form 4 insider transactions for BRVE (Braveheart Bio, Inc.), covering filings from Aug 7, 2026 onwards. 19 of those are dated within the last 90 days.
- Are BRVE insiders net buyers or net sellers?
- Across the full Form 4 history for BRVE, 13 transactions (68%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BRVE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is BRVE in?
- Braveheart Bio, Inc. (BRVE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.81B.
Methodology & sources
Every BRVE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.